Literature DB >> 23591791

A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model.

Nicola Zanesi1, Veronica Balatti, Jesse Riordan, Aaron Burch, Lara Rizzotto, Alexey Palamarchuk, Luciano Cascione, Alessandro Lagana, Adam J Dupuy, Carlo M Croce, Yuri Pekarsky.   

Abstract

TCL1 oncogene is overexpressed in aggressive form of human chronic lymphocytic leukemia (CLL) and its dysregulation in mouse B cells causes a CD5-positive leukemia similar to the aggressive form of human CLLs. To identify oncogenes that cooperate with Tcl1, we performed genetic screen in Eμ-TCL1 mice using Sleeping Beauty transposon-mediated mutagenesis. Analysis of transposon common insertion sites identified 7 genes activated by transposon insertions. Overexpression of these genes in mouse CLL was confirmed by real time reverse transcription-polymerase chain reaction. Interestingly, the main known function of 4 of 7 genes (Nfkb1, Tab2, Map3K14, and Nfkbid) is participation in or activation of the nuclear factor-kB (NF-kB) pathway. In addition, activation of the NF-kB is 1 of main functions of Akt2, also identified in the screen. These findings demonstrate cooperation of Tcl1 and the NF-kB pathway in the pathogenesis of aggressive CLL. Identification cooperating cancer genes will result in the development of combinatorial therapies to treat CLL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23591791      PMCID: PMC3663428          DOI: 10.1182/blood-2013-02-486035

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway.

Authors:  G Takaesu; S Kishida; A Hiyama; K Yamaguchi; H Shibuya; K Irie; J Ninomiya-Tsuji; K Matsumoto
Journal:  Mol Cell       Date:  2000-04       Impact factor: 17.970

Review 2.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

3.  Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RARalpha.

Authors:  Sake van Wageningen; Marleen C Breems-de Ridder; Jeannet Nigten; Gorica Nikoloski; Claudia A J Erpelinck-Verschueren; Bob Löwenberg; Theo de Witte; Daniel G Tenen; Bert A van der Reijden; Joop H Jansen
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

4.  Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system.

Authors:  Adam J Dupuy; Keiko Akagi; David A Largaespada; Neal G Copeland; Nancy A Jenkins
Journal:  Nature       Date:  2005-07-14       Impact factor: 49.962

5.  Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.

Authors:  Yuri Pekarsky; Urmila Santanam; Amelia Cimmino; Alexey Palamarchuk; Alexey Efanov; Vadim Maximov; Stefano Volinia; Hansjuerg Alder; Chang-Gong Liu; Laura Rassenti; George A Calin; John P Hagan; Thomas Kipps; Carlo M Croce
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

6.  Inhibition of JNK by cellular stress- and tumor necrosis factor alpha-induced AKT2 through activation of the NF kappa B pathway in human epithelial Cells.

Authors:  Zeng-qiang Yuan; Richard I Feldman; Mei Sun; Nancy E Olashaw; Domenico Coppola; Gene E Sussman; Sue A Shelley; Santo V Nicosia; Jin Q Cheng
Journal:  J Biol Chem       Date:  2002-06-04       Impact factor: 5.157

7.  MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1.

Authors:  N L Malinin; M P Boldin; A V Kovalenko; D Wallach
Journal:  Nature       Date:  1997-02-06       Impact factor: 49.962

Review 8.  Role of nuclear IkappaB proteins in the regulation of host immune responses.

Authors:  Masahiro Yamamoto; Kiyoshi Takeda
Journal:  J Infect Chemother       Date:  2008-08-17       Impact factor: 2.211

9.  Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.

Authors:  Yuri Pekarsky; Alexey Palamarchuk; Vadim Maximov; Alexey Efanov; Natalya Nazaryan; Urmila Santanam; Laura Rassenti; Thomas Kipps; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-08       Impact factor: 11.205

10.  Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha.

Authors:  R Meyer; E N Hatada; H P Hohmann; M Haiker; C Bartsch; U Röthlisberger; H W Lahm; E J Schlaeger; A P van Loon; C Scheidereit
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

View more
  17 in total

Review 1.  NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

Authors:  Li Yu; Ling Li; L Jeffrey Medeiros; Ken H Young
Journal:  Blood Rev       Date:  2016-10-13       Impact factor: 8.250

Review 2.  In vivo functional screening for systems-level integrative cancer genomics.

Authors:  Julia Weber; Christian J Braun; Dieter Saur; Roland Rad
Journal:  Nat Rev Cancer       Date:  2020-07-07       Impact factor: 60.716

Review 3.  Sleeping Beauty transposon insertional mutagenesis based mouse models for cancer gene discovery.

Authors:  Branden S Moriarity; David A Largaespada
Journal:  Curr Opin Genet Dev       Date:  2015-06-04       Impact factor: 5.578

Review 4.  The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.

Authors:  Yuri Pekarsky; Alessandra Drusco; Prasanthi Kumchala; Carlo M Croce; Nicola Zanesi
Journal:  Gene Expr       Date:  2015

5.  Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Ivo Veletic; Alessandra Ferrajoli; Jan Burger; Philip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Int J Cancer       Date:  2017-08-04       Impact factor: 7.396

6.  NF-κB p50 (nfkb1) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia.

Authors:  Timothy L Chen; Minh Tran; Aparna Lakshmanan; Bonnie K Harrington; Nikhil Gupta; Virginia M Goettl; Amy M Lehman; Stephen Trudeau; David M Lucas; Amy J Johnson; John C Byrd; Erin Hertlein
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

Review 7.  Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies.

Authors:  Barbara R Tschida; David A Largaespada; Vincent W Keng
Journal:  Semin Cell Dev Biol       Date:  2014-01-24       Impact factor: 7.727

Review 8.  The utility of transposon mutagenesis for cancer studies in the era of genome editing.

Authors:  Gina M DeNicola; Florian A Karreth; David J Adams; Chi C Wong
Journal:  Genome Biol       Date:  2015-10-19       Impact factor: 13.583

9.  T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.

Authors:  Ceri E Oldreive; Anna Skowronska; Nicholas J Davies; Helen Parry; Angelo Agathanggelou; Sergey Krysov; Graham Packham; Zbigniew Rudzki; Laura Cronin; Katerina Vrzalikova; Paul Murray; Elena Odintsova; Guy Pratt; A Malcolm R Taylor; Paul Moss; Tatjana Stankovic
Journal:  Dis Model Mech       Date:  2015-08-20       Impact factor: 5.758

10.  A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation.

Authors:  Gregory Lazarian; Shanye Yin; Elisa Ten Hacken; Tomasz Sewastianik; Mohamed Uduman; Alba Font-Tello; Satyen H Gohil; Shuqiang Li; Ekaterina Kim; Heather Joyal; Leah Billington; Elizabeth Witten; Mei Zheng; Teddy Huang; Mariano Severgnini; Valerie Lefebvre; Laura Z Rassenti; Catherine Gutierrez; Katia Georgopoulos; Christopher J Ott; Lili Wang; Thomas J Kipps; Jan A Burger; Kenneth J Livak; Donna S Neuberg; Fanny Baran-Marszak; Florence Cymbalista; Ruben D Carrasco; Catherine J Wu
Journal:  Cancer Cell       Date:  2021-03-08       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.